Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 141 to 150 of 242 total matches.

Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022  (Issue 1641)
to have an inadequate antibody response to COVID-19 vaccination and severe breakthrough infection requiring ...
The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) to be administered concomitantly by IM injection for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of severe allergy that prevents their vaccination against COVID-19 or moderate or severe immune compromise (see Table 1). They are the first drugs to be authorized by the FDA for this indication. Two other pairs of antibodies, bamlanivimab plus etesevimab...
Med Lett Drugs Ther. 2022 Jan 10;64(1641):1-2 |  Show IntroductionHide Introduction

An EUA for Anakinra (Kineret) for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
levels (14% vs 12%). Neutropenia, serious infections, and hypersensitivity reactions, including ...
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra (Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are...
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e203-4 |  Show IntroductionHide Introduction

Fitusiran (Qfitlia) for Hemophilia A and B

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025  (Issue 1732)
infections and nasopharyngitis. Serious thrombotic events and gall bladder disease can occur in patients ...
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected, antithrombin-directed, small interfering ribonucleic acid (siRNA), has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have hemophilia A with or without factor VIII inhibitors or hemophilia B with or without factor IX inhibitors. It is the first antithrombin-lowering therapy to become available in the US for treatment of hemophilia.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):110-1   doi:10.58347/tml.2025.1732c |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
the other S1P receptor modulators, ozanimod may increase the risk of infection and cause bradycardia and AV ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

An EUA for Bebtelovimab for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
confirmatory testing for SARS-CoV-2 infection within the previous 3 days. BLAZE-4 was completed before ...
The investigational monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death, and for whom alternative treatment options are unavailable or inappropriate. Bebtelovimab is active against the Omicron variant of SARS-CoV-2; sotrovimab (VIR-7831) is the only other monoclonal antibody currently available for treatment of COVID-19 that is active...
Med Lett Drugs Ther. 2022 Mar 21;64(1646):41-2 |  Show IntroductionHide Introduction

Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo

   
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022  (Issue 1660)
, nasopharyngitis, headache, urinary tract infection, and pyrexia. Nonmelanoma skin cancers have occurred with use ...
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be approved by the FDA for this indication. It was previously approved for treatment of atopic dermatitis.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):158-9 |  Show IntroductionHide Introduction

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
: Diarrhea, abdominal pain, nausea, and upper respiratory tract infection have been reported with use ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 |  Show IntroductionHide Introduction

Etrasimod (Velsipity) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
, dizziness, and arthralgia have been reported. Severe infections, transient reductions in heart rate ...
The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod (Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the second oral S1P receptor modulator to be approved in the US for this indication; ozanimod (Zeposia) was the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9   doi:10.58347/tml.2023.1690b |  Show IntroductionHide Introduction

Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
— Adverse effects reported with use of Eohilia in the two trials include respiratory tract infection ...
Eohilia (Takeda), an oral suspension formulation of the corticosteroid budesonide, has been approved by the FDA for treatment of eosinophilic esophagitis (EoE) in patients ≥11 years old. It is the first oral drug to be approved in the US for this indication. The subcutaneously injected interleukin (IL)-4 receptor antagonist dupilumab (Dupixent) is approved for treatment of EoE in patients ≥1 year old who weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5   doi:10.58347/tml.2024.1704c |  Show IntroductionHide Introduction

Ensifentrine (Ohtuvayre) for COPD

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
an inhaled corticosteroid (ICS). Adverse Effects: Back pain, hypertension, urinary tract infection ...
The FDA has approved ensifentrine (Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):131-3   doi:10.58347/tml.2024.1709b |  Show IntroductionHide Introduction